Hypercoagulability in a Patient with a Brain Tumor

Weinberg, Stuart; Phillips, Lydia; Twersky, Rebecca S.; Cottrell, James E.; Braunstein, Kenneth M.

doi:10.1097/00000542-198408000-00015

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sawaya and colleagues (1984) 9 , hypothesized that certain intracranial tumors may escape host antitumor fibrinolytic activity by producing plasmin inhibitors and that plasmin inhibitors may play a role in the thromboembolic complications frequently seen in patients with intracranial neoplasms. Moreover, hypercoagulability state has been demonstrated in patients with brain tumor 13 . Based on this data, it seems reasonable to believe that some patients with meningioma may present thromboembolic episodes causing reduction of CBF and neurological disfunction.…”

Section: Case Reportmentioning

confidence: 99%

Intracranial meningioma manifesting as transient ischemic attack

Cohen¹,

Júnior²,

Chaves³

et al. 2018

jbnc

View full text Add to dashboard Cite

Meningiomas are the most common intracranial primary neoplasm in adults. They present a wide variety of clinical manifestation and interpreting the symptomatology of meningiomas according to their location is one of the most fascinating topics that explore the full potential of the clinical neurologic examination. Epileptic seizures are reported as the very first symptom in most patients. However, cerebrovascular events, particularly transient ischemic attacks (TIA), are uncommon presentation of meningiomas. We describe the case of a patient with an intracranial meningioma manifesting initially as TIA and make a brief review upon the possible explanations of the event.

show abstract

Section: Case Reportmentioning

confidence: 99%

Intracranial meningioma manifesting as transient ischemic attack

Cohen¹,

Júnior²,

Chaves³

et al. 2018

jbnc

View full text Add to dashboard Cite

show abstract

“…223,224,228 In addition to the common gastrointestinal tract tumors and cancer of the pancreas, numerous other disseminated solid tumors may be the primary cause of DIC (Table 8). Unusual reports include: DIC in association with a metastasizing malignant juxtaovarian tumor, 231 DIC at the time of total hip arthroplasty for metastatic carcinoma of the proximal femur, 232 acute severe hemorrhage and thrombosis in patients with disseminated neuro blastoma, 233 chronic DIC with manifestations of hemorrhage, thrombophlebitis, and arterial em bolization in patients with primary brain tumor, 234 chronic and asymptomatic DIC in patients with oat cell carcinoma of the lung, 235 gastric metastatic adenocarcinoma to bone marrow with associated DIC and bone marrow necrosis, 236 low-grade asymptomatic DIC in patients with melanoma (es pecially if metastatic), 237 and associated with the hyperpyrexic response to bleomycin and daunorubicin for treatment of a variety of neoplasms. 238 In patients with hepatic metastases, the AT III level is usually lower but may be significantly higher than when this is not the case.…”

Section: Metastatic Solid Tumorsmentioning

confidence: 99%

Clinical Aspects of Disseminated Intravascular Coagulation: A Clinician's Point of View

Baker¹

1989

Semin Thromb Hemost

151

View full text Add to dashboard Cite

DIC is a disorder of coagulation that is demonstrated to occur in many settings. In view of the fulminant nature of the disorder once it is fully activated, the potential for considerable morbidity and mortality, and the difficulty in treating this syndrome, the necessity for a thorough understanding of the disorder is clear. A high index of suspicion is absolutely essential; however, this requires a thorough knowledge of the medical and surgical disorders in which DIC is likely to occur. The presenting manifestations of DIC, the time course of development of the fulminant syndrome, and the specific complications of the disorder may be intrinsically related to the specific clinical characteristics of the underlying disease. Clinical evaluation of the patient must be comprehensive and consider not only the laboratory and clinical manifestations of DIC but the triggering illness. Without the ability to treat the underlying primary illness, controlling or abating the DIC may be difficult or impossible. This comprehensive review of the disease entities in which DIC is likely to occur and the associated clinical manifestations will, it is hoped, guide a more precise definition of the overall clinical picture that confronts the clinician when evaluating a patient with possible DIC.

show abstract